Current treatment regimens for osteoporosis involve anti‐resorptive therapies (Yang, Jiang, et al., 2019), such as bisphosphonates, calcitonin, and estrogen, that inhibit bone resorption and maintain bone mass as well as anabolic therapies such as sclerostin antibody, Dickkopf‐1 antibody, and calcilytic agents that enhance bone formation (Gong et al., 2016). Here, CALCA is linked to osteoporosis.